Calithera (United States)

Recent papers from Calithera (United States)

1. Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelinAntibody Therapeutics · 2026
2. Skin-resident Langerhans cells drive neuropathic pain via chemokine-dependent neuron-immune communication.2026
3. TROP2 Antibody-Drug Conjugate: Unique Epitope Engagement Drives Differentiated EfficacyAntibody Therapeutics · 2026
4. Mutations of six amino acid residues in a B domain-deleted blood coagulation factor VIII have a cumulative effect on increasing its secretionResearch and Practice in Thrombosis and Haemostasis · 2025
5. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analysesNature Cancer · 2024
6. Neoadjuvant cabozantinib restores CD8 T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial2024
7. First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumoursBMJ Oncology · 2024
8. An enhancer RNA recruits MLL1 to regulate transcription of Myb2023
9. Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor ActivityJournal of Medicinal Chemistry · 2022
10. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell CarcinomaJAMA Oncology · 2022
11. Machine learning early prediction of respiratory syncytial virus in pediatric hospitalized patientsFrontiers in Pediatrics · 2022
12. Early prediction of prostate cancer risk in younger men using polygenic risk scores and electronic health recordsCancer Medicine · 2022
13. Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA TrialClinical Cancer Research · 2022
14. Analysis of MRI-derived spleen iron in the UK Biobank identifies genetic variation linked to iron homeostasis and hemolysisThe American Journal of Human Genetics · 2022
15. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialClinical Cancer Research · 2022
16. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinomaPLoS ONE · 2021
17. Comment on Conopeptide-Functionalized Nanoparticles Selectively Antagonize Extrasynaptic N-Methyl- d -Aspartate Receptors and Protect Hippocampal Neurons from Excitotoxicity In VitroACS Nano · 2021
18. A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid TumorsClinical Cancer Research · 2021
19. Receptor-ligand supplementation via a self-cleaving 2A peptide–based gene therapy promotes CNS axonal transport with functional recoveryScience Advances · 2021
20. The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated ImmunotherapiesMolecular Cancer Therapeutics · 2020